Abstract
A new approach to prevent disease recurrence in high-risk melanoma patients involves immunization with gp100 and tyrosinase peptides. This is the first study to examine the effects of such treatments on nevi. We studied biopsies of 'clinically atypical' nevi from 10 patients before and after peptide vaccination. All had a cutaneous melanoma measuring at least 1.5 mm in depth, satellite metastases, or at least one positive lymph node. We performed immunohistochemical stains for CD3, CD4, CD8, MHC-I, MHC-II, CD1a, HMB-45, MART-1, tyrosinase, bcl-2, p53, and Ki-67 (mib-1). Immunohistochemistry showed no differences in staining due to vaccination in either the immunologic or melanocytic markers. However, there was a significant increase in both p53 and bcl-2 staining, and a trend toward decreased Ki-67 staining, in the nevi post-treatment. The primary goal of peptide vaccinations with gp100 and tyrosinase is to activate melanoma-specific T cells in order to prevent melanoma recurrence. Nevi were studied in order to assess the effects on benign melanocytes. No significant changes in lymphocytes, langerhans cells, expression of MHC antigens, or melanocytic markers were found. The increase in p53 and bcl-2 raises the possibility that ...Continue Reading
References
Dec 1, 1991·The American Journal of Dermatopathology·G BenzC Schmoeckel
Dec 5, 1985·The New England Journal of Medicine·S A RosenbergJ T Vetto
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A A CreaseyT C Merigan
Dec 22, 1994·Nature·A ZieglerD E Brash
Jun 1, 1993·The British Journal of Dermatology·J M McGregorD M MacDonald
Oct 31, 1997·Journal of the American Academy of Dermatology·R A ZeffJ M Grant-Kels
Mar 21, 1998·Nature Medicine·S A RosenbergD E White
Sep 22, 1998·Annals of Surgery·S A RosenbergS M Steinberg
Oct 6, 1998·Hematology/oncology Clinics of North America·M A Weinstock
Nov 7, 1998·The Journal of Biological Chemistry·A Nalca, V M Rangnekar
Dec 29, 1998·Human Pathology·P RudolphR Parwaresch
Jul 3, 1999·Oncogene·M KortylewskiI Behrmann
Aug 24, 1999·Annals of Surgical Oncology·K M McMastersM I Ross
Dec 22, 1999·The Journal of Immunology : Official Journal of the American Association of Immunologists·M C PanelliF M Marincola
Sep 23, 2000·Journal of Immunotherapy·M FritschP H Duray
Feb 24, 2001·The American Journal of Dermatopathology·L X LiJ J Kril
Mar 31, 2001·Cancer Biotherapy & Radiopharmaceuticals·I ContastaD Adorno
May 18, 2001·Nature·S A Rosenberg
Aug 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M BalchJ F Thompson
May 9, 2002·Apoptosis : an International Journal on Programmed Cell Death·M H-L Ng
Sep 21, 2002·Science·Mark E DudleySteven A Rosenberg
Oct 31, 2002·European Journal of Clinical Investigation·E Lázár-MolnárA Falus
Oct 31, 2002·Seminars in Oncology·Boris R Minev
Dec 4, 2002·Proceedings of the National Academy of Sciences of the United States of America·Drew Pardoll
Mar 6, 2003·Journal of Surgical Oncology·Kelly M McMasters, Susan M Swetter
Jun 27, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Bataille
Jul 5, 2003·Journal of Immunotherapy·Giao Q PhanSteven A Rosenberg
Nov 25, 2003·The American Journal of Dermatopathology·Mahmoud R HusseinGary S Wood
Jan 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Matteo MarsiliFrantisek Slanina
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo